|
|
| Line 1: |
Line 1: |
| − | I'd like to send this parcel to http://www.cleansingwithfood.com/store/ methotrexate and The race for an oral, non-interferon agent could revolutionize patient care in terms of both reducing patient burden and increasing clinical outcomes. Both Johnson & Johnson with Medivir and Gilead are expected to gain approval this week; neither have experienced significant setbacks or raised concerns that would red-flag their approvals this week. However, both simeprevir and sofosbuvir are such tiny agents in the vast arsenal of products by each company that FDA approval may or may not be reflected directly in stock price.
| + | |